Exploring Current Diagnosis and Management of Amiodarone-induced Thyrotoxicosis

IF 2.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

American Journal of Cardiology Pub Date : 2025-02-07 DOI:10.1016/j.amjcard.2025.02.002

Yudi Her Oktaviono MD, PhD , Ali Mustofa BSc , Pandit Bagus Tri Saputra MD , Wynne Widiarti MD , Novia Nurul Faizah MD , Firas Farisi Alkaff MD

{"title":"Exploring Current Diagnosis and Management of Amiodarone-induced Thyrotoxicosis","authors":"Yudi Her Oktaviono MD, PhD , Ali Mustofa BSc , Pandit Bagus Tri Saputra MD , Wynne Widiarti MD , Novia Nurul Faizah MD , Firas Farisi Alkaff MD","doi":"10.1016/j.amjcard.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><div>Amiodarone, commonly used to treat various types of arrhythmias, can potentially lead to catastrophic adverse effects like amiodarone-induced thyrotoxicosis (AIT). This review offers insights into diagnosing and managing AIT, involving thyroid function tests, imaging techniques, and strategies to prevent cardiac deterioration and reduce mortality. The approach to managing AIT has shifted from focusing on thyrotoxicosis control to a broader strategy that includes preventing heart deterioration, hospitalizations, and reducing mortality. Healthcare professionals should consider the patient's need for amiodarone, side effects, coexisting conditions, and personal perspective. Routine thyroid function monitoring and collaboration across medical specialties are essential for comprehensive AIT management. Effective management of AIT is crucial to diminish mortality and morbidity. Pharmacological treatment can be initiated. Further intervention such as thyroidectomy is recommended, especially in cases where cardiac status is deteriorating and amiodarone continuation is necessary. In conclusion, early diagnosis and timely treatment through interdisciplinary collaboration according to specific individual case are crucial to reduce morbidity and mortality in AIT patients.</div></div>","PeriodicalId":7705,"journal":{"name":"American Journal of Cardiology","volume":"242 ","pages":"Pages 75-81"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002914925000736","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Amiodarone, commonly used to treat various types of arrhythmias, can potentially lead to catastrophic adverse effects like amiodarone-induced thyrotoxicosis (AIT). This review offers insights into diagnosing and managing AIT, involving thyroid function tests, imaging techniques, and strategies to prevent cardiac deterioration and reduce mortality. The approach to managing AIT has shifted from focusing on thyrotoxicosis control to a broader strategy that includes preventing heart deterioration, hospitalizations, and reducing mortality. Healthcare professionals should consider the patient's need for amiodarone, side effects, coexisting conditions, and personal perspective. Routine thyroid function monitoring and collaboration across medical specialties are essential for comprehensive AIT management. Effective management of AIT is crucial to diminish mortality and morbidity. Pharmacological treatment can be initiated. Further intervention such as thyroidectomy is recommended, especially in cases where cardiac status is deteriorating and amiodarone continuation is necessary. In conclusion, early diagnosis and timely treatment through interdisciplinary collaboration according to specific individual case are crucial to reduce morbidity and mortality in AIT patients.

查看原文本刊更多论文

探讨胺碘酮性甲状腺毒症的诊断和治疗现状。

胺碘酮，通常用于治疗各种类型的心律失常，可能会导致灾难性的不良反应，如胺碘酮诱导的甲状腺毒症（AIT）。这篇综述提供了诊断和管理AIT的见解，包括甲状腺功能检查，成像技术，以及预防心脏恶化和降低死亡率的策略。管理AIT的方法已经从关注甲状腺毒症的控制转向更广泛的策略，包括预防心脏恶化、住院治疗和降低死亡率。医疗保健专业人员应考虑患者对胺碘酮的需求、副作用、共存条件和个人观点。常规甲状腺功能监测和跨医学专业的合作是必要的全面的AIT管理。有效管理AIT对降低死亡率和发病率至关重要。可以开始药物治疗。建议进一步干预，如甲状腺切除术，特别是在心脏状况恶化和需要继续使用胺碘酮的情况下。因此，针对AIT患者的具体病例，开展跨学科合作，及早诊断，及时治疗，对于降低AIT患者的发病率和死亡率至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Cardiology 医学-心血管系统

CiteScore

4.00

自引率

3.60%

发文量

698

审稿时长

33 days

期刊介绍： Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers'' comments, and symposia.